🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS · Phase I

Neurology & CNS programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
142

Quick answer

Neurology & CNS Phase I programs: NovaPharmaNews indexes 142 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 2 of 3

  1. Divalproex Sodium Extended-release 250mg

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule active

    1 trial

  2. Donepezil Dihydroxynaphthalate for Injection

    Shanghai University of Traditional Chinese Medicine

    Alzheimer Disease

    phase 1 small molecule active

    1 trial

  3. Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 trial (METHOGLU)

    Pari Pharma GmbH

    Oncology: RELAPSED PRIMARY CNS LYMPHOMA

    phase 1 other active

    1 trial

  4. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  5. ENA-001

    BRIGHT MINDS BIOSCIENCES INC.

    Respiratory Depression

    phase 1 small molecule active

    1 trial

  6. Effect of NBI-921355 on corticospinal excitability in healthy participants

    NEUROCRINE BIOSCIENCES INC

    Epilepsy

    phase 1 other active

    1 trial

  7. First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 1 other active

    1 trial

  8. First-in-Human Study of RO7812653

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  9. GRoningen Early-PD Ambroxol Treatment Pharmacokinetics

    Disc Medicine

    Parkinson's disease

    phase 1 other active

    1 trial

  10. GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  11. Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]

    S.L

    STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder

    phase 1 small molecule active

    1 trial

  12. HEC122505MsOH

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  13. Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD)

    IONIS PHARMACEUTICALS INC

    Alzheimer’s Disease in Individuals with Down Syndrome

    phase 1 other active

    1 trial

  14. Human Amniotic Epithelial Stem Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  15. ION269

    IONIS PHARMACEUTICALS INC

    Alzheimer Disease

    phase 1 small molecule terminated

    1 trial

  16. IONIS MAPTRx

    IONIS PHARMACEUTICALS INC

    Mild Alzheimer's Disease

    phase 1 small molecule completed

    1 trial

  17. IRX4204

    IO Biotech

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  18. ITI-214 Dose A

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

  19. Infudopa i.v.

    Lxo Ireland Designated Activity Company

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  20. Ixazomib (NINLARO®) capsules / Matching placebo capsules

    Takeda

    Relapsing Remitting Multiple Sclerosis

    phase 1 small molecule active

    1 trial

  21. Jiedu Tongluo granules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Post-stroke Depression

    phase 1 small molecule completed

    1 trial

  22. KHK6640

    KYOWA KIRIN AUSTRALIA PTY LTD

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  23. KYV-101 (Biological) - 0.33 ×10^8 cells

    Kyverna Therapeutics

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

  24. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Multiple Sclerosis

    phase 1 mab active

    1 trial

  25. Ketamine

    United Therapeutics Europe Ltd

    Acute Depression

    phase 1 small molecule terminated

    1 trial

  26. LBT-3627

    Biotech Pharmaceutical Co.,

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  27. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Multiple Sclerosis (MS)

    phase 1 mab active

    1 trial

  28. LX1001

    Lexeo Therapeutics

    Alzheimer Disease

    phase 1 mab active

    1 trial

  29. LY4006896

    Eli Lilly and Company

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  30. Levodopa

    Blackmores Limited

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  31. Levodopa Cyclops®

    BRIGHT MINDS BIOSCIENCES INC.

    Parkinson

    phase 1 other completed

    1 trial

  32. Lu AF28996

    H. Lundbeck A/S

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  33. Lu AF28996 in Patients With Parkinson's Disease

    H. Lundbeck A/S

    Parkinson's Disease

    phase 1 other active

    1 trial

  34. MEDI1341

    Takeda

    Parkinson's Disease

    phase 1 small molecule completed

    2 trials

  35. MRx0029

    4D Molecular Therapeutics

    Idiopathic Parkinson Disease

    phase 1 mab terminated

    1 trial

  36. Motivational Interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 1 other completed

    1 trial

  37. N-acetylcysteine

    Ultragenyx UK Limited

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  38. NDX-1017

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  39. NMRA-323511

    Neumora Therapeutics

    Alzheimer's Disease

    phase 1 small molecule completed

    1 trial

  40. Narcan 40 MG/ML Nasal Spray

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Induced Respiratory Depression

    phase 1 small molecule active

    1 trial

  41. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  42. Obecabtagene autoleucel (obe-cel)

    Autolus GmbH

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

  43. Olanzapine Extended Release

    Teva Pharma GmbH

    Schizophrenia, Schizoaffective Disorder

    phase 1 small molecule completed

    1 trial

  44. Opicapone

    NEUROCRINE BIOSCIENCES INC

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  45. Oxcarbazepine (brand name vs generic drugs)

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule completed

    1 trial

  46. PIPE-307

    Contineum Therapeutics

    Multiple Sclerosis

    phase 1 small molecule completed

    2 trials

  47. PIPE-791

    Contineum Therapeutics

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

  48. Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment

    Bial Portela & Companhia S.A.

    Parkinson's disease

    phase 1 other active

    1 trial

Frequently asked questions

How many neurology & cns Phase I programs exist?

142 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.